|Bid||0.00 x 1100|
|Ask||0.00 x 1000|
|Day's Range||55.87 - 57.08|
|52 Week Range||48.27 - 86.58|
|Beta (3Y Monthly)||1.89|
|PE Ratio (TTM)||18.84|
|Earnings Date||Nov 6, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||68.27|
Details on presentation times or changes to presentation dates can be found on the Company's website. As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, drug discovery platform called antisense technology that can treat diseases where no other therapeutic approaches have proven effective.
Shares of Ionis Pharma jumped Wednesday after the biotech's third-quarter sales and profit easily topped Wall Street's estimates. But Perrigo and Elanco stocks dipped after their reports.
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 158.06% and 11.66%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Year-to-date revenues increased more than 50% to nearly $630 million Ionis increases 2019 revenue guidance to $1 billion Ionis significantly improves operating income and net income guidance Webcast today, ...
Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Ionis' C. Frank Bennett, Ph.D., head of research, to give keynote address - 15 presentations highlighting the transformational potential of LICA medicines for a broad range of rare and common diseases ...
CARLSBAD, Calif., Oct. 23, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (IONS), the leader in RNA-targeted therapeutics, announced today that Ionis' Chairman and Chief Executive Officer, Stanley T. Crooke, M.D., Ph.D., is one of two scientists to be awarded the 2019 Massry Prize. Dr. Crooke, who founded Ionis 30 years ago to create a radically different drug discovery platform, was recognized by the Massry Foundation for his pioneering work to establish an entirely new chemical class of medicines, antisense oligonucleotides.
CARLSBAD, Calif., Oct. 22, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (IONS) announced today that it will host a live webcast on Wednesday, November 6th at 11:30 a.m. Eastern Time to discuss its third quarter 2019 financial results and report on pipeline and business progress. As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, drug discovery platform called antisense technology that can treat diseases where no other therapeutic approaches have proven effective.
Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on Tuesday, November 5th at 4:30 p.m. Eastern Time to discuss its third quarter 2019 financial results and report on pipeline and business progress. Akcea Therapeutics, Inc., an affiliate of Ionis Pharmaceuticals, Inc. (IONS), is a biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious and rare diseases. All six drugs were discovered by Ionis, a leader in antisense therapeutics, and are based on Ionis’ proprietary antisense technology.
There are several ways to beat the market, and investing in small cap stocks has historically been one of them. We like to improve the odds of beating the market further by examining what famous hedge fund operators such as Jeff Ubben, George Soros and Carl Icahn think. Those hedge fund operators make billions of […]
A Wells Fargo analyst sees big potential in Ionis' new pipeline of drugs based on antisense oligonucleotide technology, which could prove key in the battle against ALS.
- Ionis scientists, including CEO Stanley Crooke, M.D., Ph.D., recognized with prestigious Paper of the Year Award for their work on advancing core antisense research - Ionis' Holly Kordasiewicz, Ph.D., ...
Ionis Pharmaceuticals, Inc. (IONS), the leader in RNA-targeted therapeutics, announced today that the company has been notified by its partner Bayer about the decision to advance IONIS-FXI-LRx following positive clinical results. IONIS-FXI-LRx is an antisense medicine being developed to treat patients with clotting disorders. IONIS-FXI-LRx utilizes Ionis' advanced LIgand Conjugated Antisense (LICA) technology platform and is designed to reduce the production of Factor XI (FXI), a clotting factor produced in the liver.
Shares of Akcea Therapeutics rocketed in higher-than-average volume on Monday after the Ionis Pharmaceuticals affiliate announced a licensing deal with Dow Jones component Pfizer.
Stan Crooke became the CEO of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) in 1989. This analysis aims first to contrast...
Akcea Therapeutics, Inc. (AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc. (IONS) and Pfizer Inc. (PFE), today announced that the companies have entered into a worldwide exclusive licensing agreement for AKCEA-ANGPTL3-LRx, an investigational antisense therapy being developed to treat patients with certain cardiovascular and metabolic diseases. AKCEA-ANGPTL3-LRx is designed to reduce the production of angiopoietin-like 3 (ANGPTL3) protein in the liver, a key regulator of triglycerides, cholesterol, glucose and energy metabolism. “AKCEA-ANGPTL3-LRx has the potential to treat people suffering from certain cardiovascular and metabolic diseases.
The scientific founder and CEO of Cambridge startup Dyne Therapeutics has hired a new CEO — a former CFO with experience in public stock offerings. Dyne’s current CEO, Romesh Subramanian, will be replaced by Joshua Brumm, who is leaving his post as CFO of Lexington microbiome startup Kaleido Biosciences and who has taken a California startup public.
Achillion's (ACHN) oral factor D inhibitor, danicopan, receives Breakthrough Therapy designation from the FDA as a treatment option for PNH. Shares up.
CARLSBAD, Calif., Sept. 25, 2019 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (IONS), the leader in RNA-targeted therapeutics, announced today that the California Life Sciences Association (CLSA), the trade association representing California's life sciences sector and its board of directors will honor Ionis with the 2019 Pantheon DiNA™ Award for Company of the Year. The award recognizes Ionis' ongoing commitment to growing the life sciences sector in Southern California and for achieving the approval and commercialization of SPINRAZA®, TEGSEDI® and WAYLIVRA® in major markets around the world. The award will be presented at CLSA's 16th Annual Pantheon DiNA™ Awards ceremony Nov. 15, in San Francisco, Calif.
Shares of Akcea Therapeutics Inc. sank 10% in morning trade Monday, after the biopharmaceutical company three of its top executives were leaving the company, including Chief Executive Paula Soteropoulos, effective immediately. The others leaving were President Sarah Boyce and Chief Operating Officer Jeff Goldberg. The company, which is a majority-owned affiliate of Ionis Pharmaceuticals Inc. , said it named Damien McDevitt as interim-CEO. McDevitt was previously chief business officer at Ionis. Akcea said Michael Yang and Joseph Klein have jointed its board of directors. Ionis shares tacked on 0.3%. Over the past 12 months, shares of Akcea have tumbled 27.8%, Ionis have rallied 28.0% and the S&P 500 has gained 2.0%.
Biogen (BIIB) starts a DEVOTE study to investigate whether a higher dose of Spinraza can provide greater efficacy for treating patients with spinal muscular atrophy.